IL2 and neoplasm: However, this Onc.Ad-EGFR.BiTE combined with transferred unstimulated T-cells required systemic administration of IL-2 and did not clear the tumors, suggesting that additional activation and/or persistence of T-cells at the tumor site is required to lead T-cell dependent anti-tumor effect through the BiTE molecule.